Chairman’s $1.83 Buy‑Spree at IMUNON Signals Strong Insider Confidence Amid Sharp Stock Decline.
Chairman’s large IMUNON buy signals confidence in a low‑priced, early‑stage biopharma; investors should weigh insider commitment against upcoming clinical milestones.
4 minutes to read